NewEdge Advisors’s Soleno Therapeutics SLNO Stock Holding History

NewEdge Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-175	Closed	-$5.86K	–	4366
2026 Q1	$5.86K	Hold	175	–	–	﹤0.01%	3540
2025 Q4	$8.1K	Hold	175	–	–	﹤0.01%	3531
2025 Q3	$11.8K	Hold	175	–	–	﹤0.01%	3287
2025 Q2	$14.7K	Hold	175	–	–	﹤0.01%	3055
2025 Q1	$12.5K	Hold	175	–	–	﹤0.01%	3018
2024 Q4	$7.87K	Buy	+175	New	+$9.07K	﹤0.01%	3101

NewEdge Advisors's SLNO Position: Q2 2026 in Review

NewEdge Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 175 shares — an estimated $5.86K sold.

NewEdge Advisors first reported a position in SLNO in Q4 2024 and held it in 6 quarters. The position peaked at $14.7K in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

NewEdge Advisors reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
NewEdge Advisors sold 175 Soleno Therapeutics shares in Q2 2026, an estimated $5.86K.
NewEdge Advisors first reported a position in Soleno Therapeutics in Q4 2024 and held it in 6 quarters.
NewEdge Advisors's Soleno Therapeutics position peaked at $14.7K in Q2 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.